hrs4r
 I want to donate

The Digestive Diseases and Microbiota group is interested in understanding the role of these microorganisms (bacteria among others) living in the intestine and how alterations to their proportions affect human health and disease. We are a multidisciplinary team with basic basic and clinic researchers. To respond to our research topics we are conducting clinical studies in humans and independent culture techniques focused on DNA sequencing using PCR techniques, and specifically, the 16S rRNA gene of microorganisms present in tissue samples, saliva and / or faeces from patients with different pathologies. These tools allow us to address a whole series of biological issues from a descriptive and functional perspective with the background of exploring the role of intestinal microbiota as an activating agent and as a diagnostic and prognostic tool in the field of different diseases: Crohn's disease and ulcerative colitis, colon cancer, irritable bowel syndrome, celiac disease, chronic pancreatitis, fatty liver, rheumatoid arthritis, colon, and pancreas cancer.

Main lines of research

Our main line of research is the study of microbiota in digestive diseases (inflammatory intestinal disease, colorectal cancer, chronic pancreatitis, pancreatic cancer, hepatic steatosis, hepatocarcinoma, etc.), with the intention of finding microbiological markers that can be used as prognosis, diagnosis and monitoring tools and support for these digestive pathologies.

Strategic objectives

Our group will focus its efforts around three very clear goals:

  1. Dysbiosis indicators

Work on a broad-ranging study in the correlation of indices developed during the previous period (MC and CRC) with clinical determinants of intestinal diseases for risk determination, pre-diagnosis screening and intestinal disease monitoring.

These tools for monitoring the state of the intestinal microbiota will allow delve deeper into the concept of mucous healing,  a condition that involves the reversion of a dysbiosis situation to basal or normal conditions.

  1. AIEC

Identify genetic elements involved in the pathotype "Adherent-invasive Escherichia coli' and molecular tool design for its detection in patients with Crohn's disease

  1. Hepatopancreatic line

Explore the establishment of a new line in the hepatopancreatic field dedicated to exploring the possible microbiological markers in faeces from patients with chronic pancreatitis that progress to pancreatic cancer and patients with hepatic steatosis who develop hepatocarcinoma. In fact this year (2015), Dr. Silvia Virolés has begun her thesis focusing on the study of the microbiota during the different phases of hepatic steatosis until the onset of hepatocarcinoma, with the aim of finding a microbiological marker linked to the prognosis for this disease.

Publications
Lluansí A, Llirós M, Carreras-Torres R, Bahí A, Capdevila M, Feliu A, Vilà-Quintana L, Elias-Masiques N, Cueva E, Peries L, Torrealba L, Miquel-Cusachs JO, Sàbat M, Busquets D, López C, Delgado-Aros S, Garcia-Gil LJ, Elias I, Aldeguer X

Impact of bread diet on intestinal dysbiosis and irritable bowel syndrome symptoms in quiescent ulcerative colitis: A pilot study.

Plos One, 2024, 19 dx.doi.org/10.1371/journal.pone.0297836
Mesonero F, Zabana Y, Fernández-Clotet A, Leo-Carnerero E, Caballol B, Núñez-Ortiz A, García MJ, Bertoletti F, Mínguez A, Suris G, Casis B, Ferreiro-Iglesias R, Calafat M, Jiménez I, Miranda-Bautista J, Lamuela LJ, Fajardo I, Torrealba L, Nájera R, Sáiz-Chumillas RM, González I, Vicuña M, García-Morales N, Gutiérrez A, López-García A, Benítez JM, Rubín de Célix C, Tejido C, Brunet E, Hernández-Camba A, Suárez C, Rodríguez-Lago I, Piqueras M, Castaño A, Ramos L, Sobrino A, Rodríguez-Grau MC, Elosua A, Montoro M, Baltar R, Huguet JM, Hermida B, Caballero-Mateos A, Sánchez-Guillén L, Bouhmidi A, Pajares R, Baston-Rey I, López-Sanromán A, Albillos A, Barreiro-de Acosta M

Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU.

THER ADV GASTROENTER, 2024, 17 dx.doi.org/10.1177/17562848241234476
Julià Bergkvist D, Gómez Romeu N, Pigem A, Busquets D, Farrés R, Codina-Cazador A

Robotic modified Kono-S anastomosis after ileocecal resection for Crohn's disease

TECHNIQUES IN COLOPROCTOLOGY, 2023, 27, 335-335 dx.doi.org/10.1007/s10151-022-02717-7
Lu Y, Zhao YC, Chang-Claude J, Gruber SB, Gsur A, Offit K, Vodickova L, Woods MO, Nguyen LH, Wade KH, Carreras-Torres R, Moreno V, Buchanan DD, Cotterchio M, Chan AT, Phipps AI, Peters U, Song M

Genetic Predictors for Fecal Propionate and Butyrate-Producing Microbiome Pathway are Not Associated with Colorectal Cancer Risk: A Mendelian Randomization Analysis.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2023, 32, 281-286 dx.doi.org/10.1158/1055-9965.EPI-22-0861
Acosta MB, Fernández-Clotet A, Mesonero F, García-Alonso FJ, Casanova MJ, Fernández-de la Varga M, Cañete F, de Castro L, Gutiérrez A, Sicilia B, Cano V, Merino O, de Francisco R, González-Partida I, Surís G, Torrealba L, Ferreiro-Iglesias R, Castro B, Márquez L, Sobrino A, Elorza A, Calvet X, Varela P, Vicente R, Bujanda L, Lario L, Manceñido N, García-Sepulcre MF, Iglesias E, Rodríguez C, Piqueras M, Ferrer Rosique JÁ, Lucendo AJ, Benítez O, García M, Olivares D, González-Muñoza C, López-Cauce B, Morales Alvarado VJ, Spicakova K, Brotons A, Bermejo F, Almela P, Ispízua N, Gilabert P, Tardillo C, Muñoz F, Navarro P, Madrigal Domínguez RE, Sendra P, Hinojosa E, Sáinz E, Martín-Arranz MD, Carpio D, Ricart E, Caballol B, Núñez L, Barrio J, Gisbert JP, Iborra M, Calafat M, Hernández V, Pérez RM, Cabriada JL, Domènech E, Rodríguez-Lago I

Long-term outcomes of biological therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU.

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118, 1036-1046 dx.doi.org/10.14309/ajg.0000000000002152
Mañosa M, Fernández-Clotet A, Nos P, Martín-Arranz MD, Manceñido N, Carbajo A, Hinojosa E, Hernández-Camba A, Muñoz-Pérez R, Boscá-Watts M, Calvo M, Sierra-Ausín M, Sánchez-Rodríguez E, Barreiro-de Acosta M, Núñez-Alonso A, Zabana Y, Márquez L, Gisbert JP, Guardiola J, Sáinz E, Delgado-Guillena P, Busquets D, van Domselaar M, Girona E, Lorente R, Casas-Deza D, Huguet JM, Maestro S, Cabello MJ, Castro J, Iborra M, Cañete F, Calafat M, Domènech E, ENEIDA registry by GETECCU

Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry.

DIGESTIVE AND LIVER DISEASE, 2023, 55, 46-52 dx.doi.org/10.1016/j.dld.2022.07.013
Peruchet-Noray L, Dimou N, Sedlmeier AM, Fervers B, Romieu I, Viallon V, Ferrari P, Gunter MJ, Carreras-Torres R, Freisling H

Body Shape Phenotypes and Breast Cancer Risk: A Mendelian Randomization Analysis.

Cancers, 2023, 15 dx.doi.org/10.3390/cancers15041296
Hatcher C, Richenberg G, Waterson S, Nguyen LH, Joshi AD, Carreras-Torres R, Moreno V, Chan AT, Gunter M, Lin Y, Qu C, Song M, Casey G, Figueiredo JC, Gruber SB, Hampe J, Hampel H, Jenkins MA, Keku TO, Peters U, Tangen CM, Wu AH, Hughes DA, Rühlemann MC, Raes J, Timpson NJ, Wade KH

Application of Mendelian randomization to explore the causal role of the human gut microbiome in colorectal cancer.

SCIENTIFIC REPORTS, 2023, 13, 5968-5968 dx.doi.org/10.1038/s41598-023-31840-0
Masnou H, Aguilar A, Iborra I, Sala M, Torner M, Clos-Parals A, Ardèvol A, Giménez M, Fortuny M, Sarrias MR, Morillas RM, Domènech E

Incidence, risk factors and clinical outcomes of multidrug-resistant microorganism infections among patients admitted for decompensated cirrhosis: A prospective study.

GASTROENTEROLOGIA Y HEPATOLOGIA, 2023, 46, 288-296 dx.doi.org/10.1016/j.gastrohep.2022.09.001
Aglago EK, Kim AE, Lin Y, Qu C, Evangelou M, Ren Y, Morrison J, Albanes D, Arndt V, Barry EL, Baurley JW, Berndt SI, Bien SA, Bishop DT, Bouras E, Brenner H, Buchanan DD, Budiarto A, Carreras-Torres R, Casey G, Cenggoro TW, Chan AT, Chang-Claude J, Chen X, Conti DV, Devall M, Díez-Obrero V, Dimou N, Drew D, Figueiredo JC, Gallinger S, Giles GG, Gruber SB, Gsur A, Gunter MJ, Hampel H, Harlid S, Hidaka A, Harrison TA, Hoffmeister M, Huyghe JR, Jenkins MA, Jordahl K, Joshi AD, Kawaguchi ES, Keku TO, Kundaje A, Larsson SC, Le Marchand L, Lewinger JP, Li L, Lynch BM, Mahesworo B, Mandic M, Obón-Santacana M, Moreno V, Murphy N, Nan H, Nassir R, Newcomb PA, Ogino S, Ose J, Pai RK, Palmer JR, Papadimitriou N, Pardamean B, Peoples AR, Platz EA, Potter JD, Prentice RL, Rennert G, Ruiz-Narvaez E, Sakoda LC, Scacheri PC, Schmit SL, Schoen RE, Shcherbina A, Slattery ML, Stern MC, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Tian Y, Ulrich CM, van Duijnhoven FJB, Van Guelpen B, Visvanathan K, Vodicka P, Wang J, White E, Wolk A, Woods MO, Wu AH, Zemlianskaia N, Hsu L, Gauderman WJ, Peters U, Tsilidis KK, Campbell PT

A genetic locus within the FMN1/GREM1 gene region interacts with body mass index in colorectal cancer risk.

CANCER RESEARCH, 2023, 83, 2572-2583 dx.doi.org/10.1158/0008-5472.CAN-22-3713
Competitive projects
Codi oficial: 409/C/2022 Start date:13/01/2023 Data fi: 13/01/2028 Investigador/a principal: JESÚS LIBRADO GARCÍA GIL, JOSEP ORIOL MIQUEL CUSACHS Organisme finançador: FUNDACIO LA MARATO TV3
Codi oficial: 2021 SGR 01366 Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: ROBERT CARRERAS TORRES Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER.
Codi oficial: CP21/00058 Start date:01/01/2022 Data fi: 31/12/2026 Investigador/a principal: ROBERT CARRERAS TORRES Organisme finançador: INSTITUTO DE SALUD CARLOS III
Codi oficial: 2022_GIL_JPP Start date:09/02/2023 Data fi: 08/02/2025 Investigador/a principal: JAVIER PAMPLONA PORTERO Organisme finançador: GILEAD SCIENCES, S.L.U
Transfer
Patents

López Siles Mireia, García Gil Librado Jesús, Aldeguer Manté Xavier, Martínez Medina Margarita
METHOD FOR THE QUANTIFICATION OF FAECALIBACTERIUM PRAUSNITZII PHYLOGROUP I AND/OR PHYLOGROUP II MEMBERS AND THE USE THEREOF AS BIOMARKERS
Número de publicació: WO2017025617
Data de publicació: 2017-02-16

Serra Pagès Mariona, García-Gil Jesús, Mas De Xaxars Teresa, Aldeguer Xavier
METHOD FOR DIAGNOSING COLORECTAL CANCER FROM A HUMAN FECES SAMPLE BY QUANTITIVE PCR, PRIMERS AND KIT
Número de publicació: WO2015132273
Data de publicació: 2015-09-11

 

Spin-offs

Job offers

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

menu